American Association of Cancer Research (AACR) – April 2022

AB248 is a CD8+ T cell selective IL-2 designed for superior safety and anti-tumor efficacy
Kelly D. Moynihan PhD, Danielle Pappas, Terrence Park, Wei Chen PhD, Irene Ni, Paul Bessette PhD, Henry Nguyen PhD, Mike Chin, Ruth Lan PhD, Aaron Arvey PhD, Ton N. Schumacher PhD, Andy Yeung PhD, Ivana Djuretic PhD

Selective activation of CD8+ T cells by a CD8-targeted IL-21 results in enhanced anti-tumor efficacy and safety
Renee Greer PhD, David Liu PhD, Henry Nguyen PhD, Wei Wei Prior, Meghana Sukthankar, Paul Mesko, Jeffrey Houser, Irene Ni, Mike Chin, Kelly D. Moynihan PhD, Ton N. Schumacher PhD, Ruth Lan, PhD Ivana Djuretic PhD, Andy Yeung PhD

CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor efficacy
Nathan D. Mathewson PhD, Kelly D. Moynihan PhD, Sara Sleiman PhD, Wei Chen PhD, Paul Bessette PhD, Chris Kimberlin PhD, Danielle Pappas, Terrence Park, Eric Wigton PhD, Saar Gill PhD, Andy Yeung PhD, Ivana Djuretic PhD

Protein & Antibody Engineering Summit (PEGS) Europe and Antibody Engineering & Therapeutics (AET) – November/December 2021

Engineering cis-targeted immunomodulators to enhance their selectivity and effectiveness as therapeutics
Andy Yeung, PhD

Society for Immunotherapy of Cancer (SITC) – November 2021

CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines
Hussein Sultan, PhD, Kelly Moynihan, PhD, Yuang Song, Ton Schumacher, PhD, Andy Yeung, PhD, Ivana Djuretic, PhD, and Robert D. Schreiber, PhD

Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor efficacy and safety
Kelly Moynihan, PhD, Danielle Pappas, Terrence Park, Wei Chen PhD, Irene Ni, Paul Bessette PhD, Mike Chin, Ton Schumacher, PhD, Andy Yeung, PhD, and Ivana Djuretic, PhD

 
 

This links to an external website.

Continue